Sanofi-Aventis, attraktiv niedrig bewerteter Pharmariese mit aussichtsreicher Pipeline und vielversp (Seite 44)

[orfmen]

Swine Flu Alert Closer To Pandemic Warning: Official

http://www.cnbc.com/id/30464958

[AlterSaxe]

29.04.2009 14:48
WSJ: Sanofi rechnet mit 15 Wochen für Schweinegrippe-Impfstoff

http://www.finanznachrichten.de/nachrichten-2009-04/13766478…

[CLEMENSM]

Die heute veröffentlichten Zahlen klingen sehr gut. Im Gegensatz zu manch anderer Pharmafirma wächst Sanofi zumindest beim Gewinn weiter. Kann jemand auch negative Punkte finden?

[MrBean07]

Antwort auf Beitrag Nr.: 37.055.385 von traumstrand am 28.04.09 17:25:34

Sanofi Aventis - Gewinnplus im ersten Quartal

29. Apr (Reuters) - Sanofi-Aventis SA <SASY.PA>: * Umsatz im ersten Quartal bei 7,107 Milliarden Euro (plus

2,5 Prozent) * Bereinigter Nettogewinn im ersten Quartal bei 2,178

Milliarden Euro (plus 15,7 Prozent) * Bekräftigen Prognose für 2009 mit Gewinnanstieg pro Aktie um

mindestens 7 Prozent * Analystenschätzungen für Sanofi Aventis-Umsatz im ersten

Quartal war 7,047 Milliarden Euro, für Nettogewinn 1,951

Milliarden Euro

[traumstrand]

Sanofi kann übrigens ein Gewinnler der Schweinegrippe sein, via bisherige Impfstoffe - sollte sich herausstellen, daß früher gegen "normale" Grippe mit einem H1N1-Typ Geimpfte zumindest relativ geschützt sind, ist das ein Kaufargument. Nur sieht das im gegenwärtigen Schweingrippewahn niemand - i.Ggs. zu Biotechfirmen, die noch 3-5 Jahre von der Zulassung Ihrer Substanzen weg sind...

[AlterSaxe]

Wer kann helfen?

Es geht um die Versteuerung der Dividende.
Klar ist die Abführung der 25%igen französischen Quellensteuer.
Meine Bank zieht jedoch nochmal 10,55% vom Bruttobetrag an Abgeltungssteuer ab (ohne Kirchensteuer). Kennt jemand die genaue Rechtslage? Riecht ja fast nach Doppelbesteuerung.

[GMBH]

Antwort auf Beitrag Nr.: 37.023.989 von orfmen am 23.04.09 10:22:05

Guter Hinweis, danke!

[orfmen]

Achtung!
Heute ex-Dividende-Tag!
Grüße!

[orfmen]

Do 23.04.2009 SANOFI-AVENTIS S.A. Endgültiges ex-Dividenden Datum
Di 28.04.2009 SANOFI-AVENTIS S.A. Endgültiges Dividenden Datum
Mi 29.04.2009 SANOFI-AVENTIS S.A. Ergebnisse erstes Quartal


21.04.2009 09:04
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded to Singapore and Vietnam SINGAPORE, April 21 /PRNewswire/ --

- New Studies Advance the Development of Novel Vaccine for Dengue Prevention in Asia Pacific

SINGAPORE, April 21 /PRNewswire/ --

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (News/Aktienkurs) (EURONEXT : SAN and NYSE : SNY), announced today the start of clinical studies of its investigational tetravalent dengue vaccine in Singapore and Vietnam.

With these studies, sanofi pasteur is expanding its global dengue vaccine clinical study program in Asia where trials are already ongoing in Thailand and the Philippines. These studies are aimed at advancing the development of a novel vaccine for the prevention of dengue in the Asia-Pacific region.

\"Dengue has emerged as a serious public health problem in Asia-Pacific in the last decades. There are 1.8 billion people in the region at risk of dengue fever,\" said Chusak Prasittisuk, Coordinator Communicable Diseases Control at the World Health Organization South East- Asia Region. \"WHO is committed to fostering vaccine development for the control of dengue disease in Asia.\"

Currently, there is no specific treatment available against dengue fever, which is the most widespread tropical disease after malaria. Sanofi Pasteur is collaborating with the Communicable Disease Center in Singapore and the Pasteur Institute in Vietnam to conduct these clinical studies in children and adults.

\"Controlling the mosquitoes that transmit dengue is necessary but not sufficient to fight against the disease. A safe and effective vaccine has been long awaited to prevent dengue epidemics,\" said Professor Leo Yee Sin, director of the Communicable Disease Center in Singapore. \"Clinical studies in Singapore are critical steps to advance the development of a vaccine for the prevention of dengue in Asia. We are happy to contribute to scientific research that would benefit the entire region.\"

\"Fighting against dengue is a main public health priority in Vietnam. About 100,000 people are infected each year, mostly children,\" said Dr. Tran Ngoc Huu, director of Pasteur Institute in Ho Chi Minh City. \"The Pasteur Institute is committed to supporting clinical studies for a dengue vaccine that would ultimately benefit children in Vietnam.\"

A global clinical study program across endemic regions in Asia and Latin America

Sanofi Pasteur started the development of a dengue vaccine in the \'90s. Clinical studies with the most advanced tetravalent candidate vaccine started in the 2000s. Sanofi Pasteur tetravalent dengue vaccine candidate has been evaluated in clinical trials in adults and children from non-endemic and endemic countries (U.S., Mexico, Philippines). Overall, a balanced immune response against all four serotypes was observed after three doses of the vaccine. The vaccine appears to be well tolerated with a similar safety profile after each dose(1). Sanofi Pasteur\'s dengue vaccine research program includes ongoing clinical studies in Mexico, Peru, The Philippines and Thailand, with adults and children. The goal of the pediatric clinical study in Thailand is to assess the efficacy of the vaccine in protecting children against symptomatic dengue infection. Sanofi Pasteur\'s tetravalent dengue vaccine candidate is the first to reach this stage of clinical development.

About dengue fever

Dengue fever is a mosquito-borne disease caused by four types of dengue viruses (type 1 to 4). Overall, the disease is a potential threat for almost half the world\'s population. Of the estimated 230 million people infected annually, two million, mostly children, develop dengue hemorrhagic fever (DHF), a severe form of the disease(2). DHF is a leading cause of hospitalization in South-East Asia, placing tremendous pressure on strained medical resources.

Dengue fever occurs mostly in tropical and subtropical countries and is spreading to new parts of the globe each year. The WHO has warned that the Western Pacific Region may be heading for a major dengue outbreak(3). Outbreaks recently have been observed in Paraguay and the Middle East. In addition, dengue affects countries such as Australia (Queensland) and the United States (Puerto Rico, Texas-Mexico border, Hawaii and the US-affiliated Pacific Islands). A substantial number of people traveling to endemic regions are also infected each year.

About sanofi-aventis

[MrBean07]

Antwort auf Beitrag Nr.: 37.011.965 von traumstrand am 21.04.09 19:05:14

Gemeint ist bloß der Fertigpen Solostar, also 50 Mios von diesen Pens, mit dem die Tagesdosis Lantus (wird in Deutschland produziert) verabreicht wird.